| Literature DB >> 34926535 |
Chao Li1, Wei Wang2, Shuai-Shuai Xie1, Wen-Xian Ma1, Qian-Wen Fan1, Ying Chen1, Yuan He1, Jia-Nan Wang1, Qin Yang1, Hai-di Li1, Juan Jin3, Ming-Ming Liu1, Xiao-Ming Meng1, Jia-Gen Wen1.
Abstract
Sepsis is a systemic inflammatory response syndrome caused by infection, following with acute injury to multiple organs. Sepsis-induced acute kidney injury (AKI) is currently recognized as one of the most severe complications related to sepsis. The pathophysiology of sepsis-AKI involves multiple cell types, including macrophages, vascular endothelial cells (ECs) and renal tubular epithelial cells (TECs), etc. More significantly, programmed cell death including apoptosis, necroptosis and pyroptosis could be triggered by sepsis in these types of cells, which enhances AKI progress. Moreover, the cross-talk and connections between these cells and cell death are critical for better understanding the pathophysiological basis of sepsis-AKI. Mitochondria dysfunction and oxidative stress are traditionally considered as the leading triggers of programmed cell death. Recent findings also highlight that autophagy, mitochondria quality control and epigenetic modification, which interact with programmed cell death, participate in the damage process in sepsis-AKI. The insightful understanding of the programmed cell death in sepsis-AKI could facilitate the development of effective treatment, as well as preventive methods.Entities:
Keywords: acute kidney injury; apoptosis; necroptosis; pyroptosis; sepsis
Year: 2021 PMID: 34926535 PMCID: PMC8674574 DOI: 10.3389/fmed.2021.796724
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1The programmed death of macrophages, ECs, and TECs in sepsis-AKI. In sepsis, PAMPs and/or DAMPs that are released from damaged tissues activate and increase the pro-inflammatory phenotype (M1) forms of macrophages, leading to the release of pro-inflammatory cytokines which can cause damage to the kidney tissue of bystanders. PAMPs/DAMPs and etc present in the plasma can induce the dysfunction and cell death of vascular ECs. Abnormalities in the contraction and relaxation of local blood vessels, as well as the formation of microthrombus, result in the restriction of local blood supply and microcirculation disorders. Apoptosis and pyroptosis of ECs result in the increasing of vascular permeability. Thereafter, a large amount of fluid, endotoxin and inflammatory factors and cells permeated into the renal interstitium, further exacerbating local hypoxia. The infiltrating inflammatory cells and inflammatory factors, as well as the ROS, attacked TECs. Finally, TECs undergo apoptosis, pyroptosis and necroptosis, leading to AKI.
Figure 2Cellular signaling in regulating programmed cell death of TECs. Under the stimulation of DAMPs/PAMPs, TLR4 is activated and initiates the downstream NOX4 signal. The enhanced connection between SH3YL1 and the anchoring protein P22phox of NOX4, stabilizes and activate NOX4, leading to the production of ROS and further mitochondrial injury. Furthermore, RIPK3 can also directly bind and stabilize NOX4 and bring it to mitochondria, causing mitochondria dysfunction. On the other hand, ROS and activated TNFR are the main inducements of necroptosis. In an oxygen-deficient environment, mitochondria dysfunction can lead to the production of ROS, which activates p53 and causes apoptosis. On the contrary, p53 further activates the formation of Bax dimers which are translocated to the outer membrane of mitochondria leading to the release of mitochondrial cyto C and other potential proinflammatory substances including membrane lipids, ATP, and oxidized form of mtDNA. The substance leaked from mitochondria, triggered the assembly and activation of the NLRP3 inflammasome, causing cell pyroptosis. Besides, NLRP3 can also be activated by the PAMPs entered through endocytosis. NLRP3 captured adaption protein ASC and further activated caspase-1 that led to maturation of inflammatory factors IL-18 and IL-1β and the cleavage of GSDMD. Moreover, TLR4 can activate the NF-κB signaling pathway which transcriptionally regulates the production of TNF-α, IL-1β, IL-18, and NLRP3. Caspase-11 in mice and its homologs in humans (caspase-4/5) can be directly activated by PAMPs, independent of NLRP3 activation. Finally, the cleaved GSDMD by caspase-1 formed the structure of membrane pores, leading to the release of pro-inflammatory cytokines, damage associated molecular patterns (DAMPs) and other cellular contents. After releasing to the extracellular environment, DAMPs and pro-inflammatory cytokines further aggravated the necroptosis and pyroptosis, in cycles.
The intervention drugs of programmed cell death in sepsis-AKI.
|
|
|
|
|
|
|---|---|---|---|---|
| Apoptosis | DL-propargylglycine | Decreasing Bax, P53 and inflammation | LPS-RAW264.7 | ( |
| Resveratrol | Decreasing iNOS, Bcl-2 and Bcl-xL in macrophages; inhibiting macrophages activation, cytokine release and TLR4 activation | LPS-Mice | ( | |
| Adiponectin | Decreasing GRP78, CHOP and caspase-12; attenuating endoplasmic reticulum stress IRE1α pathway and ROS | CLP-Rat; LPS-HUVEC | ( | |
| SW033291 | Inhibiting 15-PGDH; increasing Bcl-2, downregulating Fas, caspase-3, caspase-8; downregulating lipid peroxidation and oxidative stress | LPS-Mice | ( | |
| SPA0355 | Inhibiting P53 signaling pathway, inflammation, oxidative stress | LPS-Mice | ( | |
| Dihydroartemisinin | Inhibiting caspase-3, inflammation, oxidative stress | LPS-Mice | ( | |
| Ginkgetin aglycone | Upregulating SIRT1, blocking inflammation | LPS-Mice; LPS-HK-2 | ( | |
| Geniposide | Activating PPARγ; increasing Bcl-2; decreasing Bax and cleaved caspase-3; reducing vascular permeability, inflammation and oxidative stress | CLP-Mice; LPS-HK-2 | ( | |
| Neferine | Upregulating Klotho, reducing inflammation | LPS-Mice; LPS-NRK52E | ( | |
| TMP195 | Inhibiting IIa HDACs, increasing Bax and cleaved caspase3, decreasing Bcl-2 and bone morphogenetic protein-7, mitigating inflammation | LPS-Mice; LPS-Murine RTEC | ( | |
| Dexmedetomidine | Reducing MALAT1, ALKBH5 and inflammation | LPS-HK-2 | ( | |
| AICAR or metformin | Increasing Sirt3, activating AMPK, restorating mitochondrial function and metabolic fitness | CLP-Mice; LPS+HMGB1-HK-2 | ( | |
| Paricalcitol | Increasing vitamin D receptor and Bcl2, decreasing cleaved caspase-3 | LPS-Mice | ( | |
| Arbutin | Regulating PI3K/Akt/Nrf2 pathway; increasing Bcl-2; decreasing Bax, caspase-3, and caspase-9 | LPS-Rat; LPS-NRK-52e | ( | |
| (–)-epigallocatechin-3-gallate | Inhibiting Sema3A; increasing Bcl-2; decreasing Bax and cleaved caspase-3 | LPS-Mice; LPS-NRK52E | ( | |
| Pyroptosis | CC-5013 | Inhibiting TNF-α/HMGB1 signaling pathway and inflammation | LPS/D-Gal,mice;LPS-M1 macrophage | ( |
| HCAG | Decreasing NLRP3, caspase-1, IL-1β, IL-18, TLR4 and MyD88; inhibiting phosphorylation of AKT and PKC-α/δ | LPS-RAW264.7; LPS-Mice | ( | |
| Samotolisib | Inhibiting PI3K/AKT/ mTOR pathway, Nedd4 and caspase-11 | LPS-Mice; LPS-RAW264.7 | ( | |
| Mdivi-1 | Inhibiting DLP1; reducing NLRP3, cleaved caspase-1, GSDMD, IL-1β and IL-18 | LPS-Mice; LPS-Mouse RTEC | ( | |
| Znpp | Inhibiting HO-1/PINK1, inflammation and oxidative stress; regulating mitochondria fusion/fission | LPS-Rat | ( | |
| AC-YVAD-CMK | Inhibiting caspase-1; decreasing NLRP-1, IL-1β, IL-18 and GSDMD | CLP-Mice | ( | |
| C16(C13H8N4OS) | Inhibiting protein kinase R, decreasing ASC, NLRP3, caspase-1 | LPS-Mice | ( | |
| Thymoquinone | Decreasing NLRP3, caspase-1, caspase-3, caspase-8, and inflammation | CLP-Mice | ( | |
| N-acetyl-L-cysteine | Removing ROS, decreasing cleaved caspase-1, NLRP3, and cleaved GSDMD | LPS-HUVECs | ( | |
| HU308 | Increasing cannabinoid receptor 2; decreasing NLRP3, caspase-1 and GSDMD activation | CLP-Mice; LPS-BMDM | ( | |
| Necroptosis | Bosentan | Blocking ET receptors; decreasing TLR4, MyD88 and phosphorylation of RIPK3; improving cell migration property | LPS- BMVECs | ( |
| Necrostatin-1 | Inhibiting RIPK1; decreasing LC3-II and p62 | LPS-Mice | ( | |
| Autophagy | Resveratrol or quercetin | Activating Sirt1, deacetylating P53 | CLP/LPS-Mice; LPS-RTEC | ( |
| 2-DG | Inhibiting aerobic glycolysis, activating Lactic/SIRT3/AMPK pathway | CLP-Mice; LPS-HK-2 | ( | |
| Dexmedetomidine | Decreasing NLRP3,IL-1β and IL-18, ASC, caspase-1 and cleaved caspase-1; | LPS-Rat | ( |